Article

Homologous and heterologous antibody responses to a one-year booster dose of an MF59 (R) Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

University of Tampere Medical School
Human Vaccines & Immunotherapeutics (Impact Factor: 3.64). 07/2012; 8(7):921-8. DOI: 10.4161/hv.20248
Source: PubMed

ABSTRACT Background: Primary immunization with two doses of MF59 (®) -adjuvanted A/H5N1 influenza vaccine has been shown to be highly immunogenic and well tolerated in children and adolescents. Assessment of long-term antibody persistence after priming, and the effects of a one-year booster dose in children and adolescents was needed. Objectives This study assessed homologous and heterologous antibody responses to a one-year booster dose of MF59-adjuvanted A/H5N1 influenza vaccine in previously primed children. Subjects and methods: Twelve months after primary vaccination, toddlers, children and adolescents received a single booster dose of the same A/H5N1 vaccine. Paired sera were collected before and three weeks after booster vaccination. Homologous antibody responses against the A/Vietnam/1194/2004 vaccine strain were measured by hemagglutination inhibition (HI), single radial hemolysis (SRH) and microneutralization (MN) assays. Heterologous antibody responses against A/Indonesia/5/2005 and A/Anhui/1/2005 strains were assessed by MN assay only. Results: Twelve months after primary vaccination, persistent, homologous, seroprotective HI antibody titers (≥ 40) were observed in 46%, 26% and 30% of toddlers, children and adolescents; following booster vaccination, seroprotection rates increased to 99%, 98% and 91%, respectively. All toddlers and children, and 99% of adolescents achieved MN antibody titers ≥ 40. Cross-reactive A/H5N1 antibodies were detected in 94-98% of subjects after booster vaccination. Conclusions Two priming doses of MF59-adjuvanted A/H5N1 vaccine resulted in homologous and heterologous antibody responses which persisted for up to one year after immunization. A one-year booster dose was highly immunogenic, generating high homologous and cross-reactive A/H5N1 antibody titers.

0 Followers
 · 
99 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal. This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non-adjuvanted, trivalent, influenza vaccine (TIV) in Guatemalan children (N = 360) between 6 and < 60 months of age. Methodology: Children received two doses of ATIV or TIV administered four weeks apart. Solicited adverse reactions were recorded for seven days after each vaccination. Serious adverse events were recorded throughout the entire study period. Antibody responses were assessed by hemagglutination inhibition (HI) assay at baseline, four weeks after administration of the first vaccine dose, and three weeks after administration of the second dose. Results: Both ATIV and TIV were well tolerated, with similar rates of solicited reactions and adverse events observed in response to both vaccines. MF59-adjuvanted vaccine induced considerably higher antibody titers than did TIV. After two doses, the B strain-specific antibody response to TIV was insufficient to meet the Center for Biologics Evaluation and Research (CBER) licensure criterion for seroprotection, whereas responses to the MF59-adjuvanted vaccine met the seroprotection criterion against all three strains. Cross-reactive antibody responses to MF59-adjuvanted vaccine met the CBER seroprotection criterion against all three strains after two doses; B strain-specific heterologous responses to non-adjuvanted TIV were inadequate. Conclusions: The MF59-adjuvanted seasonal influenza vaccine was well-tolerated and highly immunogenic in children 6 to < 60 months of age, inducing seroprotective antibody titers against both the vaccine strains and antigenically distinct heterologous strains.
    The Journal of Infection in Developing Countries 09/2014; 8(9):1160-8. DOI:10.3855/jidc.4594 · 1.27 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inactivated influenza vaccines are produced every year to fight against the seasonal epidemics of influenza. Despite the nonoptimal coverage, even in subjects at risk like the elderly, pregnant women, etc., these vaccines significantly reduce the burden of mortality and morbidity linked to the influenza infection. Importantly, these vaccines have also contributed to reduce the impact of the last pandemics. Nevertheless, the performance of these vaccines can be improved mainly in those age groups, like children and the elderly, in which their efficacy is suboptimal. The use of adjuvants has proven effective to this scope. Oil-in-water adjuvants like MF59 and AS03 have been licensed and widely used, and shown efficacious in preventing influenza infection in the last pandemic. MF59-adjuvanted inactivated vaccine was more efficacious than non-adjuvanted vaccine in preventing influenza infection in young children and in reducing hospitalization due to the influenza infection in the elderly. Other adjuvants are now at different stages of development and some are being tested in clinical trials. The perspective remains to improve the way inactivated vaccines are prepared and to accelerate their availability, mainly in the case of influenza pandemics, and to enhance their efficacy/effectiveness for a more successful impact at the public health level.
    Current topics in microbiology and immunology 07/2014; DOI:10.1007/82_2014_406 · 3.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies on candidate pandemic vaccines against avian influenza virus have focussed on H5N1, but viruses of other subtypes, such as A/H9N2, are also considered to have pandemic potential. We investigated the safety and immunogenicity of two immunizations with one of five different antigen doses (ranging from 3.75 to 45 μg hemagglutinin antigen) of a non-adjuvanted, whole-virus G9-lineage H9N2 vaccine in healthy adults aged 18-49 years. Antibody responses were measured by hemagglutination inhibition (HI), microneutralization (MN) and single radial hemolysis (SRH) assays. To investigate a hypothesis that previous exposure to H2N2 viruses in subjects born in or before 1968 might prime for more robust antibody responses to H9N2 vaccination, a post-hoc age-stratified analysis of antibody responses was done. Both vaccinations in all dose groups were safe and well-tolerated. No vaccine-related serious adverse events were reported, and the majority of adverse reactions were rated as mild. Injection site reaction rates were lower in the 3.75 μg and 7.5 μg dose groups compared to the higher dose groups; systemic reaction rates were similar across all dose groups. Seroprotection rates among the different dose groups 21 days after the second immunization ranged from 52.8% to 88.9% measured by HI assay, from 88.7% to 98.1% or 82.7% to 96.2% measured by MN assay (MN titer cut-off 1:40 and 1:80, respectively), and from 94.2% to 100% measured by SRH assay. Higher antibody responses were not induced in subjects born in or before 1968. These data indicate that a non-adjuvanted, whole-virus H9N2 vaccine is well-tolerated and immunogenic in healthy adults.
    Clinical and vaccine Immunology: CVI 10/2014; DOI:10.1128/CVI.00275-14 · 2.37 Impact Factor